Latest medullary thyroid cancer Stories
- Data Presented This Week at ENDO 2015 Annual Meeting - SOUTH SAN FRANCISCO, Calif., March 6, 2015 /PRNewswire/ -- Veracyte,
SOUTH SAN FRANCISCO, Calif., Feb.
SOUTH SAN FRANCISCO, Calif., Dec.
Launched in Conjunction with Thyroid Cancer Awareness Month, aMTCSupport.com Offers Resources and Support for Rare Disease Community WILMINGTON, Del., Sept.
- Decisions to Cover Afirma for Use in Thyroid Cancer Diagnosis Bring Total Number of "Blues" Covered Lives to More than 10 Million - SOUTH SAN FRANCISCO, Calif., July 3, 2014 /PRNewswire/
SOUTH SAN FRANCISCO, Calif., May 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of its
SOUTH SAN FRANCISCO, Calif., May 6, 2014 /PRNewswire/ -- Veracyte, Inc.
A specific protein once thought to exist only in the brain may play a crucial role in a deadly form of thyroid cancer, as well as other cancers, and provide a fresh target for researchers seeking ways to stop its progression
Researchers at the National Institutes of Health (NIH), Bethesda, MD, have taken the first steps to determine if a protein, called Programmed Death Ligand 1 (PD-L1), can help to predict which thyroid cancer patients will most likely have a recurrence of the disease.
- An armed gangster.